A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/40 (2006.01) A61K 31/00 (2006.01) A61K 31/395 (2006.01) A61K 31/407 (2006.01) A61K 41/00 (2006.01)
Patent
CA 2253608
A method for inhibiting VEGF stimulated endothelial cell growth, such as associated with neoplasia, and VEGF stimulated capillary permeability, such as associated with pulmonary edema are disclosed, particularly using the .beta.- isozyme selective PKC inhibitor, (S)-3,4-[N,N'-1,1'-((2''-ethoxy)-3'''(O)-4'''- (N,N-dimethylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione hydrochloride salt.
Cette invention concerne un procédé destiné à inhiber, d'une part, la croissance cellulaire de l'endothélium stimulée par le facteur de croissance de l'endothélium vasculaire, telle qu'elle est associée à la néoplasie, et, d'autre part, la perméabilité capillaire stimulée par ledit facteur de croissance, telle qu'elle est associée à l'oedème pulmonaire. Le procédé utilise en particulier l'inhibiteur sélectif du .beta.-isozyme de la protéine kinase C, le sel chlorydrate de (S)-3,4-[N,N'-1,1'-((2''-éthoxy)-3'''(O)-4'''-(N,N-diméthylamino)-butane)-bis-(3,3'-indolyl)]-1(H)-pyrrole-2,5-dione.
Aiello Lloyd P.
Jirousek Michael R.
King George L.
Vignati Louis
Ways Douglas Kirk
Eli Lilly And Company
Gowling Lafleur Henderson Llp
LandOfFree
Therapeutic treatment for vegf related diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic treatment for vegf related diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic treatment for vegf related diseases will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1443608